Status:
COMPLETED
Quality of Life and Health Economic Measurements in Allergic Patients Treated With Immunotherapy
Lead Sponsor:
Aalborg University
Conditions:
Hypersensitivity
Asthma
Eligibility:
All Genders
16+ years
Brief Summary
Grass pollen and house dust mites (HDM) are the most common allergens causing allergic rhino-conjunctivitis (RC) and/or asthma (A). Subcutaneous allergen specific immunotherapy (SCIT) reduces symptoms...
Eligibility Criteria
Inclusion
- Adults (\> 16 years) and allergic to grass pollen and/or house dust mites.
Exclusion
- Allergic patients who had been immunotherapy treated before.
Key Trial Info
Start Date :
November 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
571 Patients enrolled
Trial Details
Trial ID
NCT01486498
Start Date
November 1 2005
End Date
November 1 2011
Last Update
December 6 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.